NCT05938543 Cerebellar TMS and Satiety in Prader-Willi Syndrome
| NCT ID | NCT05938543 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Prader-Willi Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2023-09-01 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study hyperphagia and satiety in Prader-Willi syndrome. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study, the investigators will be stimulating the brain to learn more about how TMS might improve hyperphagia in Prader-Willi syndrome.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Prader-Willi syndrome Exclusion Criteria: * contraindications for TMS or MRI including : * history of neurological disorder * history of head trauma resulting in loss of consciousness * history of seizures or diagnosis of epilepsy or first degree relative family history of epilepsy * metal in brain or skull * implanted devices such as a pacemaker, medication pump, nerve stimulator or ventriculoperitoneal shunt claustrophobic in MRI
Contact & Investigator
Laura Holsen, PhD
PRINCIPAL INVESTIGATOR
Brigham and Women's Hospital
Frequently Asked Questions
Who can join the NCT05938543 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Prader-Willi Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05938543 currently recruiting?
Yes, NCT05938543 is actively recruiting participants. Contact the research team at lholsen@bwh.harvard.edu for enrollment information.
Where is the NCT05938543 trial being conducted?
This trial is being conducted at Belmont, United States.
Who is sponsoring the NCT05938543 clinical trial?
NCT05938543 is sponsored by Brigham and Women's Hospital. The principal investigator is Laura Holsen, PhD at Brigham and Women's Hospital. The trial plans to enroll 20 participants.